<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Neurologic manifestations of rheumatoid arthritis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Neurologic manifestations of rheumatoid arthritis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Neurologic manifestations of rheumatoid arthritis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Monica L Piecyk, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter H Schur, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">E William St Clair, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael J Aminoff, MD, DSc</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Philip Seo, MD, MHS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 19, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Rheumatoid arthritis (RA) is associated with various nonarticular manifestations, including a range of neurologic abnormalities, such as cervical spine instability, compressive neuropathy (eg, of the median nerve at the wrist, which results in carpal tunnel syndrome [CTS]), and an often subclinical sensory or sensorimotor axonal neuropathy; as well as rare manifestations including central nervous system (CNS) vasculopathy, rheumatoid meningitis, and ischemic neuropathy due to rheumatoid vasculitis (RV) [<a href="#rid1">1</a>]. Muscle disorders may also occur, and some medications used in RA infrequently have adverse neurologic effects.</p><p>Neurologic and muscular disorders associated with RA will be reviewed here. Other nonarticular and non-neurologic problems associated with RA are presented separately, as are detailed discussions of the clinical manifestations, diagnosis, and treatment of RV. (See  <a class="medical medical_review" href="/z/d/html/7511.html" rel="external">"Overview of the systemic and nonarticular manifestations of rheumatoid arthritis"</a> and  <a class="medical medical_review" href="/z/d/html/8237.html" rel="external">"Clinical manifestations and diagnosis of rheumatoid vasculitis"</a> and  <a class="medical medical_review" href="/z/d/html/8228.html" rel="external">"Treatment of rheumatoid vasculitis"</a>.)</p><p class="headingAnchor" id="H1684777395"><span class="h1">CLASSIFICATION AND EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Neurologic and muscular complications of rheumatoid arthritis (RA) may occur by several mechanisms, including direct effects of compression or invasion of neural tissues and as a consequence of vasculitic neuropathy. Rheumatoid synovitis and pannus may compress or invade adjacent structures (including the spinal cord and peripheral nerves), resulting in myelopathy, radiculopathy, and entrapment neuropathies.</p><p>Vasculitic neuropathy is a frequent component of rheumatoid vasculitis (RV), although RV itself is infrequent; the neuropathy in these patients results from infarction of individual peripheral nerves by vasculitis affecting the vasa nervorum [<a href="#rid2">2-4</a>]. Cerebral vasculitis is rarely associated with RA [<a href="#rid5">5</a>]. It has been hypothesized that damage to endothelium may trigger thrombus formation, which might result in ischemia or hemorrhage in that area served by the blood vessel [<a href="#rid5">5</a>].</p><p>More than half of patients with RA can exhibit a peripheral neuropathy on electrophysiologic studies, but less than half of these are symptomatic or have signs on examination [<a href="#rid6">6</a>]. A sensory neuropathy is most common; sensorimotor changes can also occur [<a href="#rid7">7,8</a>]. Approximately 40 percent of patients with RV have a sensory neuropathy, and up to 20 percent develop manifestations of a mixed motor and sensory neuropathy. Both mononeuritis multiplex and a distal symmetric sensory or sensorimotor neuropathy can occur [<a href="#rid2">2,9,10</a>]. (See <a class="local">'Noncompressive neuropathies'</a> below and  <a class="medical medical_review" href="/z/d/html/8237.html" rel="external">"Clinical manifestations and diagnosis of rheumatoid vasculitis"</a>.)</p><p>Central nervous system (CNS) involvement can rarely cause rheumatoid meningitis or a CNS vasculitis. Although rare, CNS involvement may cause ischemia, infarction, or bleeding that may result in transient ischemic attacks, stroke, quadriplegia, or paraparesis. (See <a class="local">'Central nervous system'</a> below and  <a class="medical medical_review" href="/z/d/html/8237.html" rel="external">"Clinical manifestations and diagnosis of rheumatoid vasculitis", section on 'Neurologic disease'</a>.)</p><p>The introduction of biologic medications, along with more aggressive and effective strategies for the treatment of RA, has coincided with a reduction in the frequency of some of the neurologic and other extraarticular manifestations of RA [<a href="#rid11">11-13</a>].</p><p class="headingAnchor" id="H2"><span class="h1">CENTRAL NERVOUS SYSTEM</span><span class="headingEndMark"> — </span>Disorders of the central nervous system (CNS) due to rheumatoid arthritis (RA) itself are rare. These conditions include cervical myelopathy, vasculitis, rheumatoid nodules located within the CNS, meningitis, and, very rarely, progressive multifocal leukoencephalopathy (PML). PML, when it does occur, is usually in association with use of immunosuppressive medications.</p><p>Stroke also occurs with increased frequency, but the basis for this association is not well understood. Cerebral involvement is rare and is more likely to represent diseases not unique to RA, such as arteriosclerotic cerebrovascular disease, embolic stroke, or infection (especially in the context of immunosuppression) [<a href="#rid14">14</a>]. Posterior reversible encephalopathy syndrome (PRES) has been reported [<a href="#rid15">15</a>].</p><p class="headingAnchor" id="H3"><span class="h2">Cervical myelopathy</span><span class="headingEndMark"> — </span>Cervical myelopathy (cervical myeloradiculopathy) resulting from atlantoaxial subluxation, atlantoaxial impaction, and/or subaxial subluxation is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7518.html" rel="external">"Cervical subluxation in rheumatoid arthritis"</a>.)</p><p class="headingAnchor" id="H4"><span class="h2">Central nervous system vasculitis</span><span class="headingEndMark"> — </span>CNS vasculitis is rare in patients with RA, with the literature consisting of case reports of intracranial arteritis [<a href="#rid16">16-23</a>]. CNS lesions, as described below, are also infrequent on imaging (by a range of techniques) in patients with systemic rheumatoid vasculitis (RV), which can affect both small and medium-sized arteries in which the histopathologic changes of involved medium-sized vessels are similar to those of polyarteritis nodosa [<a href="#rid9">9,22,24,25</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – Headache and mental status changes were the most common reported symptoms in these cases [<a href="#rid8">8,16-23,26</a>]. Seizures, cranial nerve palsies, blindness, paralysis, dementia, aphasia, gait disorders, and intracranial hemorrhage have also been reported. Fever is not typically present, and blood pressure is usually normal.</p><p></p><p class="bulletIndent1">In most reports, patients with CNS vasculitis had a long duration of erosive, seropositive RA with rheumatoid nodules [<a href="#rid16">16,18-20,22,25,27</a>]. However, not all patients had synovitis at the time of vasculitis diagnosis. Isolated spinal vasculitis has also been reported in a patient with longstanding seropositive RA [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent1">The erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) are typically elevated [<a href="#rid27">27</a>]. Cerebral spinal fluid (CSF) with high protein, pleocytosis, and low glucose suggests RA with CNS involvement, but not all patients exhibit these findings [<a href="#rid29">29</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – CNS vasculitis should be suspected when some of the reported clinical features are present and cannot be otherwise explained by an infection, malignancy, medication side effect, metabolic abnormalities, or other conditions. A brain biopsy is the most specific diagnostic test and is needed to make a definitive diagnosis. If there are signs of vasculitis in other organs or tissues, a biopsy of that lesion may be helpful. The diagnostic approaches to CNS and other forms of vasculitis are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/8230.html" rel="external">"Primary angiitis of the central nervous system in adults", section on 'Diagnostic approach'</a> and  <a class="medical medical_review" href="/z/d/html/8226.html" rel="external">"Overview of and approach to the vasculitides in adults"</a>.)</p><p></p><p class="bulletIndent1">Findings on magnetic resonance imaging (MRI) and computed tomographic (CT) angiography are nonspecific. In patients with neurologic features suggesting a CNS process, we obtain a brain MRI scan and CT angiography to identify abnormalities supporting the diagnosis and to help exclude other disorders that may have a similar clinical presentation. In rheumatoid CNS vasculitis, a brain MRI typically shows T2 hyperintensities in the subcortical and periventricular white matter, and CT angiography of the brain may be normal or show nonspecific vascular abnormalities. A normal brain MRI helps exclude the possibility of CNS vasculitis, while an abnormal MRI with subcortical T2 hyperintensities is nonspecific for this diagnosis.</p><p></p><p class="bulletIndent1">Conventional angiography often does not show signs of vasculitis. Moreover, evidence suggests that MRI abnormalities among symptomatic patients with RA cannot be ascribed to vasculitis alone but may be due to unrelated factors. One study, for example, compared the incidence of hyperintense white matter lesions detected by brain MRI scan in 33 asymptomatic patients with RA and 48 control individuals [<a href="#rid30">30</a>]; the results showed no significant difference in the number of such lesions between the two groups.</p><p></p><p class="bulletIndent1">CSF findings alone cannot be used to exclude CNS vasculitis in RA [<a href="#rid8">8</a>]; they are neither sufficiently sensitive nor specific but may be useful in supporting the diagnosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – The treatment of CNS vasculitis in patients with RA is similar to that for patients with isolated CNS vasculitis. This includes high-dose glucocorticoids and cytotoxic agents. (See  <a class="medical medical_review" href="/z/d/html/8230.html" rel="external">"Primary angiitis of the central nervous system in adults", section on 'Treatment'</a>.)</p><p></p><p class="headingAnchor" id="H8"><span class="h2">Rheumatoid nodules</span><span class="headingEndMark"> — </span>Rheumatoid nodules have been reported rarely in the CNS [<a href="#rid29">29,31</a>]. Most patients with CNS nodules have severe seropositive erosive joint disease, peripheral subcutaneous rheumatoid nodules, high titer rheumatoid factors, and, less commonly, additional extraarticular features, including pulmonary or ocular involvement [<a href="#rid32">32-34</a>]. (See  <a class="medical medical_review" href="/z/d/html/7523.html" rel="external">"Rheumatoid nodules"</a>.)</p><p>Rheumatoid nodules have been reported in cerebral leptomeninges and within the choroid plexus [<a href="#rid21">21,33-37</a>]. Extradural nodules in the spinal canal may cause nerve root compression, spinal cord compression, and spinal stenosis [<a href="#rid32">32,38</a>].</p><p>These nodules are typically detected by MRI and, if suspected, proven to be rheumatoid in nature by biopsy. Biopsy is performed only if clinically warranted due to diagnostic uncertainty and if the results will affect management. A nodule causing neurologic symptoms can be unexpected. In one case, for example, a patient with transient ischemic attack-like episodes was found to have leptomeningeal enhancement on brain MRI, which was later found on meningeal biopsy to be rheumatoid nodules [<a href="#rid37">37</a>]. In another example, a patient underwent laminectomy for persistent severe symptoms of left lower extremity radiculopathy and was found to have a rheumatoid nodule causing S1 and S2 nerve root compression [<a href="#rid32">32</a>].</p><p>No medication has been reported effective in inducing regression of CNS rheumatoid nodules. Rheumatoid nodules attributed to <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> (MTX) in other locations have regressed in up to 70 percent of patients an average of six months after MTX was stopped [<a href="#rid39">39,40</a>]. <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">Rituximab</a> was effective treatment for one patient with severe subcutaneous nodules [<a href="#rid41">41</a>]. Surgical decompression should be performed if a rheumatoid nodule is compressing a vital structure.</p><p class="headingAnchor" id="H9"><span class="h2">Rheumatoid meningitis</span><span class="headingEndMark"> — </span>Rheumatoid meningitis, or aseptic meningitis in a patient with RA, is a rare condition characterized by an inflammatory infiltrate of the meninges without distinct rheumatoid nodules [<a href="#rid29">29,42-50</a>]. Most patients have longstanding seropositive disease [<a href="#rid49">49</a>]. Symptoms are variable between patients and may include altered mental status, fever, headaches, seizures, cranial nerve dysfunction, and hemiparesis or paraparesis. Fever is more commonly reported than in RA patients with CNS rheumatoid nodules or CNS vasculitis.</p><p>Rheumatoid meningitis should be suspected in patients whose brain MRI scan shows meningeal thickening and/or enhancement (enhancement may be restricted to only the pachymeninges [<a href="#rid49">49</a>]); examination of the CSF helps to exclude infectious and carcinomatous meningitis. Elevated CSF protein is the most common abnormality, but pleocytosis and depressed glucose have also been described. Diagnosis relies on examination of a meningeal biopsy, with presence of plasma cells, and rheumatoid nodules [<a href="#rid51">51</a>]. Rheumatoid factor and anti-citrullinated peptide antibodies have been detected in the CSF in a small number of cases [<a href="#rid50">50,51</a>]. (See  <a class="medical medical_review" href="/z/d/html/15759.html" rel="external">"Autoimmune (including paraneoplastic) encephalitis: Clinical features and diagnosis"</a>.)</p><p>In several case reports, treatment with pulse glucocorticoids (<a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> 250 to 1000 mg intravenously [IV] daily for three days) followed by an oral <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> taper improved neurologic symptoms [<a href="#rid44">44,45,49,52,53</a>]. In another case, a patient with rheumatoid meningitis had resolution of severe seizures and MRI abnormalities after treatment with two doses of <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> (two infusions of 1 g each, with a two-week interval between infusions) plus methylprednisolone 250 mg IV daily for three consecutive days followed by an oral prednisone taper [<a href="#rid47">47</a>].</p><p>Rheumatoid meningitis has occurred in patients treated with tumor necrosis factor (TNF) inhibitors [<a href="#rid54">54-56</a>]. In all of these patients, the TNF inhibitor was stopped; most were also treated with glucocorticoids with resolution of their presenting neurologic symptoms.</p><p class="headingAnchor" id="H11"><span class="h2">Progressive multifocal leukoencephalopathy</span><span class="headingEndMark"> — </span>PML, which is associated with the polyoma John Cunningham (JC) virus, has been reported, although rarely, in patients with RA taking immunosuppressive agents, most frequently <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>. However, the absolute risk of developing PML in RA is very small. In an observational study from the United States using a nationwide inpatient sample database, the rate of PML in hospitalized patients with RA was estimated at 0.4 per 100,000 discharges, twice the rate in the background population [<a href="#rid57">57</a>]. (See  <a class="medical medical_review" href="/z/d/html/1694.html" rel="external">"Progressive multifocal leukoencephalopathy (PML): Epidemiology, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/8280.html" rel="external">"Overview and virology of JC polyomavirus, BK polyomavirus, and other polyomavirus infections"</a> and  <a class="medical medical_review" href="/z/d/html/7501.html" rel="external">"Rituximab: Principles of use and adverse effects in rheumatoid arthritis", section on 'Hypogammaglobulinemia and infection'</a>.)</p><p>The clinical manifestations and diagnosis of PML and its management are the same in patients with and without RA. (See  <a class="medical medical_review" href="/z/d/html/1694.html" rel="external">"Progressive multifocal leukoencephalopathy (PML): Epidemiology, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/8280.html" rel="external">"Overview and virology of JC polyomavirus, BK polyomavirus, and other polyomavirus infections"</a> and  <a class="medical medical_review" href="/z/d/html/1697.html" rel="external">"Progressive multifocal leukoencephalopathy (PML): Treatment and prognosis"</a>.)</p><p>The estimated absolute risk of PML is one case per 25,000 patients with RA treated with <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> [<a href="#rid58">58</a>]. PML was reported in only two patients with RA prior to the use of biologic disease-modifying antirheumatic drugs (DMARDs) [<a href="#rid59">59</a>]. There has been at least one case reported in association with use of <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a> in RA [<a href="#rid60">60</a>] and another in a patient treated with <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">tocilizumab</a> [<a href="#rid61">61</a>]. There have been at least two cases of leukoencephalopathy in an RA patient treated with MTX [<a href="#rid62">62,63</a>].</p><p class="headingAnchor" id="H12"><span class="h2">Hyperviscosity syndrome</span><span class="headingEndMark"> — </span>Hyperviscosity syndrome has been reported in a very small number of patients with seropositive RA. Its clinical manifestations are typically similar to those of Waldenström macroglobulinemia, including headache, visual changes, vertigo, tinnitus, hearing loss, and cognitive dysfunction [<a href="#rid64">64</a>]. This syndrome is discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/6657.html" rel="external">"Epidemiology, pathogenesis, clinical manifestations, and diagnosis of Waldenström macroglobulinemia", section on 'Hyperviscosity syndrome'</a>.)</p><p class="headingAnchor" id="H13"><span class="h2">Stroke</span><span class="headingEndMark"> — </span>Both traditional cardiovascular risk factors and markers of RA severity contribute to an increased cardiovascular risk in patients with RA, including for stroke and transient ischemic attack, as well as for myocardial infarction [<a href="#rid65">65</a>]. By contrast, reduced RA disease activity and use of MTX and/or TNF-alpha inhibitors are associated with fewer cardiovascular events, including fewer strokes [<a href="#rid66">66-68</a>].</p><p>A 2008 meta-analysis, involving 111,758 patients in 24 studies, found a significant increase in the risk of death from cerebrovascular accidents in patients with RA, compared with the general population (weighted-pooled summary estimate of standardized mortality ratios of 1.52, 95% CI 1.40-1.67) [<a href="#rid69">69</a>]. Significant heterogeneity, however, was found between the studies analyzed, and some studies, including those in one population-based cohort, have not shown stroke to be increased [<a href="#rid70">70</a>]. Nevertheless, most studies have shown an increased risk of stroke in RA. For example:</p><p class="bulletIndent1"><span class="glyph">●</span>In a nested case-control analysis within a longitudinal databank of 16,990 patients with RA, 226 first strokes, of which 59 were ischemic and occurred more often in patients with RA compared with patients that had noninflammatory rheumatic disease (odds ratio [OR] 1.64 for all first strokes, 95% CI 1.16-2.30 and 2.66 for ischemic strokes, 95% CI 1.24-5.70) [<a href="#rid71">71</a>]. Risk factors for ischemic stroke included severity of RA, hypertension, myocardial infarction, and low-dose <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> use but not diabetes, smoking, exercise, or body mass index. Treatment with rofecoxib and possibly antecedent treatment with glucocorticoids were other possible risk factors.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An increase in stroke was noted in a population-based study of 25,385 Canadian adults with RA, compared with age- and sex-matched controls [<a href="#rid72">72</a>]. The patients with RA had a small but significant absolute increase in stroke risk (2.4 per 1000 person-years, rate ratio 1.9, 95% CI 1.7-2.1). The absolute increase in overall cardiovascular events in RA patients was much greater in those over age 65.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A nationwide Danish cohort study involving 18,247 patients with RA followed for a median of 4.8 years identified 718 strokes in patients with RA, representing an absolute increase in stroke incidence compared with the general population (1.9 per 1000 person-years, with an adjusted incidence rate ratio of 1.32, 95% CI 1.22-1.42) [<a href="#rid73">73</a>]. The risk of atrial fibrillation was also increased in patients with RA, but the degree to which this contributed to stroke risk was not determined. (See  <a class="medical medical_review" href="/z/d/html/129796.html" rel="external">"Overview of heart disease in rheumatoid arthritis", section on 'Atrial fibrillation'</a>.)</p><p></p><p>As in the general population, the risk of stroke in patients with RA increases with herpes zoster infection, with a 2.3-fold increased risk in the 90 days after infection shown in a large cohort of RA patients from Taiwan [<a href="#rid74">74</a>]. (See  <a class="medical medical_review" href="/z/d/html/8271.html" rel="external">"Varicella zoster virus vasculopathy"</a>.)</p><p>Cardiovascular risk management in patients with RA includes emphasizing the benefits of lifestyle modification (eg, healthy diet, exercise, and smoking cessation), addressing the traditional risk factors for atherosclerotic disease (eg, hypertension, dyslipidemia, and diabetes) and treating with disease-modifying agents to reduce RA disease activity. (See  <a class="medical medical_review" href="/z/d/html/7492.html" rel="external">"Coronary artery disease in rheumatoid arthritis: Implications for prevention and management"</a>.)</p><p class="headingAnchor" id="H14"><span class="h1">PERIPHERAL NERVOUS SYSTEM</span><span class="headingEndMark"> — </span>Peripheral neuropathies, including both compressive (entrapment) and noncompressive neuropathies, are the most common neurologic manifestations of rheumatoid arthritis (RA). (See <a class="local">'Compression or entrapment neuropathy'</a> below and <a class="local">'Noncompressive neuropathies'</a> below.)</p><p>In addition to entrapment neuropathies (eg, carpal tunnel syndrome [CTS]), noncompressive neuropathies may cause sensory and motor nerve dysfunction. Estimates of the frequency of the different types of peripheral nerve involvement vary depending on the methods for patient selection and the extent of neurologic testing.</p><p class="bulletIndent1"><span class="glyph">●</span>A 2014 review found that the most common disorders of the peripheral nervous system in patients with RA were mononeuritis multiplex, sensorimotor neuropathy, and entrapment neuropathy [<a href="#rid4">4</a>]. Almost one-half of sural nerve biopsies are normal in patients with sural nerve involvement by electrophysiologic studies [<a href="#rid4">4,6,75,76</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a series of 33 nondiabetic patients with RA, electrodiagnostic testing found 6 percent of these patients had CTS and 17 percent had mononeuritis multiplex [<a href="#rid75">75</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another study of 108 patients with RA, pure sensory or sensory motor axonal neuropathy accounted for 85 percent of abnormal electrophysiological studies, while the remainder showed demyelinating neuropathy [<a href="#rid6">6</a>].</p><p></p><p class="headingAnchor" id="H15"><span class="h2">Compression or entrapment neuropathy</span><span class="headingEndMark"> — </span>Entrapment neuropathies are diagnosed in up to 45 percent of patients with RA, according to a 2002 report [<a href="#rid14">14</a>]. A more recent literature analysis from 2016 reported a 14 percent prevalence of subclinical CTS in patients with RA [<a href="#rid77">77</a>]. Compared with controls, the odds ratio (OR; adjusted for body mass index [BMI]) of CTS in patients with RA was 2.43 [<a href="#rid78">78</a>]. Joint deformities and inflamed synovium, ligaments, or tendon sheaths may compress peripheral nerves in close proximity to joints or bursae. There is no correlation between compression neuropathies and sex, duration of RA, functional class, the presence of other extraarticular disease, seropositivity, or the level of acute phase reactants [<a href="#rid79">79</a>]. (See <a class="local">'Carpal tunnel syndrome'</a> below and <a class="local">'Tarsal tunnel syndrome'</a> below and <a class="local">'Other compressive neuropathies'</a> below.)</p><p>Electromyography (EMG) and nerve conduction studies are the most useful tests for evaluating suspected compression of peripheral nerves; ultrasonography has also been utilized [<a href="#rid80">80,81</a>]. In patients suspected of a compressive neuropathy based upon symptoms and findings, we perform an EMG and nerve conduction study and ultrasound to determine the anatomic site of compression.</p><p>Nonsurgical management involves treatment of the underlying disease process. Otherwise, treatment of these syndromes is the same as in patients without RA. Additional modalities may include splints, antiinflammatory medications, and local glucocorticoid injections. Surgical decompression is sometimes indicated if motor deficits or denervation are present or if sensory symptoms worsen despite adequate nonsurgical therapy [<a href="#rid6">6,81,82</a>]. (See  <a class="medical medical_review" href="/z/d/html/5287.html" rel="external">"Carpal tunnel syndrome: Treatment and prognosis"</a> and  <a class="medical medical_review" href="/z/d/html/6669.html" rel="external">"Surgery for carpal tunnel syndrome"</a> and  <a class="medical medical_review" href="/z/d/html/5282.html" rel="external">"Overview of upper extremity peripheral nerve syndromes"</a> and  <a class="medical medical_review" href="/z/d/html/5278.html" rel="external">"Overview of lower extremity peripheral nerve syndromes"</a>.)</p><p class="headingAnchor" id="H16"><span class="h3">Carpal tunnel syndrome</span><span class="headingEndMark"> — </span>CTS, which is due to compression of the median nerve as it travels through the carpal tunnel of the wrist, is commonly associated with pain and paresthesia, and less commonly weakness, in the median nerve distribution. Symptoms are often worse at night or with activities involving wrist flexion, and sometimes occur in the volar forearm. CTS is detected in 6 to 10 percent of RA patients undergoing electrophysiologic studies [<a href="#rid6">6,75,76</a>]. In one study, there was a 6.8 percent incidence of CTS in 1070 patients with RA, and the CTS did not correlate with disease activity or duration of RA [<a href="#rid83">83</a>].</p><p>Clinical manifestations, diagnosis, and treatment of CTS are similar in patients with RA to those without RA and are described in detail separately. (See  <a class="medical medical_review" href="/z/d/html/5288.html" rel="external">"Carpal tunnel syndrome: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/5258.html" rel="external">"Carpal tunnel syndrome: Pathophysiology and risk factors"</a> and  <a class="medical medical_review" href="/z/d/html/5287.html" rel="external">"Carpal tunnel syndrome: Treatment and prognosis"</a> and  <a class="medical medical_review" href="/z/d/html/6669.html" rel="external">"Surgery for carpal tunnel syndrome"</a>.)</p><p class="headingAnchor" id="H17"><span class="h3">Tarsal tunnel syndrome</span><span class="headingEndMark"> — </span>Tarsal tunnel syndrome is uncommon; it is due to compression of the tibial nerve as it passes near the medial malleolus [<a href="#rid84">84</a>]. It may result from tenosynovitis, inflammation of the flexor retinaculum, or valgus deformities. (See  <a class="medical medical_review" href="/z/d/html/5278.html" rel="external">"Overview of lower extremity peripheral nerve syndromes", section on 'Tarsal tunnel syndrome'</a>.)</p><p>Symptoms include paresthesia and pain in the sole of the foot and the first through third toes. Findings of atrophy and weakness of the intrinsic foot muscles occur with more advanced disease. Prior to the availability of biologic medications, from 5 to 25 percent of RA patients had electrophysiologic abnormalities characteristic of tarsal tunnel syndrome, although not all of these patients were symptomatic [<a href="#rid84">84-87</a>].</p><p>Treatment of tarsal tunnel syndrome in patients with RA is similar to the approach for patients without RA. (See  <a class="medical medical_review" href="/z/d/html/5278.html" rel="external">"Overview of lower extremity peripheral nerve syndromes", section on 'Tarsal tunnel syndrome'</a>.)</p><p class="headingAnchor" id="H18"><span class="h3">Other compressive neuropathies</span><span class="headingEndMark"> — </span>Although unusual, compression of other peripheral nerves has been reported in patients with RA. Affected nerves include the anterior and posterior interosseous, ulnar, common peroneal, and tibial [<a href="#rid82">82,88-93</a>]. Median nerve entrapment at the elbow causes pronator teres syndrome; ulnar nerve entrapment at the elbow causes cubital tunnel syndrome and at the wrist, Guyon canal syndrome [<a href="#rid81">81</a>]. Femoral nerve palsy complicates distended synovitis of the hip and may lead to sensory and motor defects [<a href="#rid87">87</a>]. The common peroneal and tibial nerves may be compressed by a popliteal cyst. (See  <a class="medical medical_review" href="/z/d/html/14924.html" rel="external">"Popliteal (Baker's) cyst"</a>.)</p><p>The term "double crush" syndrome refers to the concurrent presentation of an entrapment neuropathy and symptomatic cervical spine disease with nerve root compression [<a href="#rid88">88</a>].</p><p class="headingAnchor" id="H20"><span class="h2">Noncompressive neuropathies</span><span class="headingEndMark"> — </span>Several forms of noncompressive neuropathy are seen in patients with RA, including a distal sensory neuropathy; a less common combined sensorimotor neuropathy; and an autonomic neuropathy. Neuropathic abnormalities detected by nerve conduction studies and EMG studies, which are more common in patients with RA than in controls, are most often axonal, although demyelinating features are sometimes present [<a href="#rid6">6,94</a>]. Before biologic medications were available, distal sensory neuropathy and sensorimotor neuropathy were reported in 1 to 18 percent of patients in the first several years of disease [<a href="#rid95">95</a>]. Pathologic findings range from normal histopathology to perineural thickening to vasculopathy, and rarely, vasculitis or amyloidosis, suggesting these neuropathies have varied pathogenesis [<a href="#rid6">6,9,90,93,96-98</a>].</p><p class="headingAnchor" id="H21"><span class="h3">Distal sensory neuropathy</span><span class="headingEndMark"> — </span>Peripheral sensory polyneuropathy, which typically presents in a slowly progressive fashion and is generally not associated with rheumatoid vasculitis (RV), has the following clinical features:</p><p class="bulletIndent1"><span class="glyph">●</span>Symmetric paresthesias and burning sensations, which tend to be worse in the feet than in the hands [<a href="#rid90">90,96,99</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Discomfort that may be difficult to distinguish from myalgia and arthralgia but is neuropathic in origin [<a href="#rid90">90,96</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Decreased vibratory, pinprick, and light touch sensation</p><p class="bulletIndent1"><span class="glyph">●</span>Decreased or absent deep tendon reflexes, and abnormalities of both sensory and motor nerve conduction [<a href="#rid96">96,98</a>]</p><p></p><p>In one study of 25 patients, neuropathy usually developed after the arthritis, and there was no relation between duration of RA and neuropathy [<a href="#rid96">96</a>]. Studies employing sural nerve biopsy most often reveal mild proliferative endarteritis or normal vasculature with segmental demyelination and remyelination and areas of axonal degeneration [<a href="#rid97">97,98</a>]. There is mild loss of predominantly large myelinated fibers [<a href="#rid89">89,96</a>]. The yield of biopsy may be low, given the mild pathologic changes and patchy distribution of lesions.</p><p>It is important to exclude other causes of peripheral neuropathy, including vitamin deficiency and diabetes. (See  <a class="medical medical_review" href="/z/d/html/5284.html" rel="external">"Overview of polyneuropathy"</a>.)</p><p class="headingAnchor" id="H22"><span class="h3">Combined sensorimotor neuropathy</span><span class="headingEndMark"> — </span>Combined sensorimotor neuropathy is rare; it is usually due to ischemic neuropathy caused by RV. Both symmetric sensorimotor neuropathy and asymmetric mononeuritis multiplex ("vasculitis") have been described in case reports of patients with RA. Other clinical features in these patients include long-duration seropositive, nodular RA, male sex, other extraarticular involvement, systemic constitutional symptoms, palpable purpura, livedo reticularis, skin ulcerations, nailfold and digital infarcts, and Raynaud phenomenon [<a href="#rid9">9,90,93,96,98-101</a>]. High rheumatoid factor titers, a polyclonal increase in immunoglobulins (Igs), and low complement levels are also common. (See  <a class="medical medical_review" href="/z/d/html/8237.html" rel="external">"Clinical manifestations and diagnosis of rheumatoid vasculitis", section on 'Neurologic disease'</a>.)</p><p>Combined sensorimotor neuropathy is more severe and presents more acutely than distal sensory neuropathy [<a href="#rid90">90,96</a>]. Symptoms include significant asymmetric pain and paresthesias. Weakness may develop within hours to days of the initial onset of symptoms. Wrist and foot drops are most common, and deep tendon reflexes are decreased or absent. Electrophysiologic studies demonstrate axonal degeneration or severe demyelination [<a href="#rid96">96,98</a>]. These findings are suggestive of nerve damage due to vasculitis. (See  <a class="medical medical_review" href="/z/d/html/8221.html" rel="external">"Treatment and prognosis of nonsystemic vasculitic neuropathy"</a>.)</p><p>The following observations relate to vasculitic neuropathy seen specifically in patients with RA:</p><p class="bulletIndent1"><span class="glyph">●</span>Arterial pathology of affected peripheral nerves includes fibrinoid necrosis of the media with infiltration by polymorphonuclear leukocytes, eosinophils, and mononuclear cells. Perivascular infiltration with mononuclear cells, intimal proliferation with minimal cellular infiltrates, and/or fibrosis can also be observed [<a href="#rid98">98</a>]. Vasculitis of the epineural arteries results in vessel ischemia with resulting axonal degeneration and neuronal demyelination [<a href="#rid91">91,98</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The arteritis may be immune complex-mediated. Sural nerve examination has demonstrated IgG, IgM, complement, and fibrin depositions in areas of acute necrotizing arteritis, while these deposits are usually absent in vessels without acute inflammation [<a href="#rid99">99</a>].</p><p></p><p>The treatment of sensorimotor neuropathy due to RV is described in detail separately. (See  <a class="medical medical_review" href="/z/d/html/8228.html" rel="external">"Treatment of rheumatoid vasculitis"</a>.)</p><p class="headingAnchor" id="H23"><span class="h3">Autonomic neuropathy</span><span class="headingEndMark"> — </span>An increased incidence of autonomic neuropathy, as determined by abnormal cardiovascular reflexes, has been reported [<a href="#rid102">102</a>]. Autonomic nervous system dysfunction has been noted in 15 to 47 percent of RA patients [<a href="#rid103">103-105</a>].</p><p class="headingAnchor" id="H24"><span class="h1">MUSCLE DISORDERS</span><span class="headingEndMark"> — </span>In patients with rheumatoid arthritis (RA), muscle weakness is common. In the era before 1980, muscle weakness and/or atrophy were observed in approximately one-third of patients [<a href="#rid106">106</a>]. Muscle disorders in patients with RA include myopathy (eg, due to disuse or glucocorticoid therapy) and frank myositis.</p><p class="headingAnchor" id="H25"><span class="h2">Myopathy</span><span class="headingEndMark"> — </span>Myopathy in patients with RA includes disuse atrophy, glucocorticoid-induced myopathy, and myositis.</p><p class="headingAnchor" id="H26"><span class="h3">Disuse atrophy</span><span class="headingEndMark"> — </span>Sarcopenia was newly classified as a disease entity in 2016; it is characterized by low muscle mass and low skeletal muscle strength or low physical performance [<a href="#rid107">107</a>]. Sarcopenia occurs especially in older adults and is frequently associated with RA. Muscle weakness and wasting can result from disuse due to synovitis and pain. This is most commonly seen in RA patients who have knee pain and/or inflammation resulting in quadriceps weakness and when hands and wrists become inflamed and/or are painful, resulting in decreased grip strength. Muscle biopsy reveals type II fiber atrophy; there is no muscle inflammation, necrosis, regeneration, or vasculitis [<a href="#rid97">97,106,108,109</a>]. Effective treatment requires adequate medical therapy for the RA to control joint inflammation and reduce pain, which is followed by a strengthening exercise program. (See  <a class="medical medical_review" href="/z/d/html/5155.html" rel="external">"Approach to the patient with muscle weakness"</a>.)</p><p>Chronic inflammation due to RA may also directly impair muscle function via effects on muscle metabolism and adipose tissue [<a href="#rid110">110</a>].</p><p class="headingAnchor" id="H29"><span class="h3">Glucocorticoid-induced myopathy</span><span class="headingEndMark"> — </span>Glucocorticoid-induced or steroid myopathy is characterized by proximal muscle weakness without significant serum muscle enzyme elevations. Muscle biopsy reveals type II fiber atrophy [<a href="#rid109">109,111</a>]. Gradual reduction in the glucocorticoid dose and a muscle strengthening rehabilitation program are the mainstays of treatment. (See  <a class="medical medical_review" href="/z/d/html/5171.html" rel="external">"Glucocorticoid-induced myopathy"</a> and  <a class="medical medical_review" href="/z/d/html/7983.html" rel="external">"Glucocorticoid withdrawal"</a>.)</p><p class="headingAnchor" id="H30"><span class="h2">Myositis</span><span class="headingEndMark"> — </span>Very infrequently, inflammatory myositis can occur as part of an overlap syndrome with RA [<a href="#rid112">112,113</a>]. Histopathology shows myofiber necrosis and regeneration, with focal or diffuse infiltration of lymphocytes, plasma cells, and mononuclear cells into the endomysium, perimysium, and perivascular areas [<a href="#rid97">97,106,108,114</a>]. (See  <a class="medical medical_review" href="/z/d/html/5160.html" rel="external">"Initial treatment of dermatomyositis and polymyositis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/127066.html" rel="external">"Overview of and approach to the idiopathic inflammatory myopathies", section on 'Overlap syndromes'</a>.)</p><p class="headingAnchor" id="H31"><span class="h1">AMYLOID</span><span class="headingEndMark"> — </span>Rheumatoid arthritis (RA) may rarely be complicated by AA (secondary) amyloidosis, which may result in abnormalities in both the central and peripheral nervous systems [<a href="#rid17">17</a>]. Amyloid deposits have been reported in brain arterioles in four patients with RA and central nervous system (CNS) vasculitis [<a href="#rid18">18,19</a>]. Peripheral neuropathy can also result from AA amyloidosis [<a href="#rid17">17</a>]. (See  <a class="medical medical_review" href="/z/d/html/5602.html" rel="external">"Causes and diagnosis of AA amyloidosis and relation to rheumatic diseases"</a>.)</p><p class="headingAnchor" id="H32"><span class="h1">DRUGS</span><span class="headingEndMark"> — </span>Medications utilized to treat rheumatoid arthritis (RA) can lead to various neurologic complications [<a href="#rid4">4</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Nonsteroidal antiinflammatory drugs (NSAIDs) may result in headaches, drowsiness, and aseptic meningitis. (See  <a class="medical medical_review" href="/z/d/html/7991.html" rel="external">"Nonselective NSAIDs: Overview of adverse effects"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Glucocorticoids can cause myopathy, depression, psychosis, and benign intracranial hypertension. (See  <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a> and <a class="local">'Glucocorticoid-induced myopathy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antimalarials, such as <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">hydroxychloroquine</a>, can cause dizziness, headache, tinnitus, seizures, and neuromyopathy. (See  <a class="medical medical_review" href="/z/d/html/7964.html" rel="external">"Antimalarial drugs in the treatment of rheumatic disease"</a> and  <a class="medical medical_review" href="/z/d/html/5166.html" rel="external">"Drug-induced myopathies"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Gold therapy, which is mostly of historical interest, can be complicated by peripheral neuropathy, cranial nerve palsies, and Guillain-Barré syndrome [<a href="#rid115">115</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">Methotrexate</a> (MTX) can cause headaches and impair the ability to concentrate. (See  <a class="medical medical_review" href="/z/d/html/7509.html" rel="external">"Major side effects of low-dose methotrexate"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">Sulfasalazine</a> and <a class="drug drug_general" data-topicid="10097" href="/z/d/drug information/10097.html" rel="external">leflunomide</a> can both cause headaches. (See  <a class="medical medical_review" href="/z/d/html/7524.html" rel="external">"Sulfasalazine: Pharmacology, administration, and adverse effects in the treatment of rheumatoid arthritis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10097" href="/z/d/drug information/10097.html" rel="external">Leflunomide</a> is associated with peripheral neuropathy. (See  <a class="medical medical_review" href="/z/d/html/7515.html" rel="external">"Pharmacology, dosing, and adverse effects of leflunomide in the treatment of rheumatoid arthritis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tumor necrosis factor (TNF)-alpha inhibitors may increase the risk of demyelinating disorders of the central nervous system (CNS). Very rarely, progressive multifocal leukoencephalopathy (PML) and peripheral neuropathy have been reported in patients treated with anti-TNF therapies (as it has with <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>). (See  <a class="medical medical_review" href="/z/d/html/7970.html" rel="external">"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects", section on 'Demyelinating disease'</a> and <a class="local">'Progressive multifocal leukoencephalopathy'</a> above.)</p><p></p><p class="headingAnchor" id="H1689845"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – Neurologic abnormalities associated with rheumatoid arthritis (RA) can result from compression or infiltration of the spinal cord or nerves by rheumatoid synovitis and pannus and from nerve damage from rheumatoid vasculitis (RV). (See <a class="local">'Classification and epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Central nervous system manifestations</strong> – Disorders of the central nervous system (CNS) that are associated with RA are infrequent, but include cervical myelopathy, rheumatoid nodules located within the CNS, meningitis, vasculitis, and, very rarely, progressive multifocal leukoencephalopathy (PML). Stroke, particularly ischemic stroke, occurs with increased frequency in patients with RA. Therapy of patients with RA and CNS vasculitis is similar to that for patients with isolated CNS vasculitis. (See <a class="local">'Central nervous system'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Compression neuropathies</strong> – Compression neuropathies are the most common neurologic manifestation of RA. The most common entrapment neuropathy in RA is carpal tunnel syndrome (CTS). Other syndromes due to nerve compression or entrapment include tarsal tunnel syndrome, due to compression of the tibial nerve near the medial malleolus; syndromes involving the anterior and posterior interosseous, ulnar, common peroneal, and tibial nerves; cervical nerve root compression; and common peroneal and tibial nerve compression from popliteal cysts. (See <a class="local">'Compression or entrapment neuropathy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Noncompressive neuropathies</strong> – Noncompressive neuropathies include both distal sensory neuropathy, which is usually slowly progressive, and sensorimotor neuropathy, which may have a more acute presentation and which occurs in more severely affected patients with seropositive nodular disease and other extraarticular manifestations. An increased incidence of autonomic neuropathy may also be present in patients with RA. (See <a class="local">'Noncompressive neuropathies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Muscle disorders</strong> – Muscle disorders can occur in RA and may result in muscle weakness and/or atrophy. These disorders include disuse muscle atrophy and glucocorticoid myopathy. Myositis rarely occurs in patients with RA and may be due to an autoimmune overlap syndrome. (See <a class="local">'Muscle disorders'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug side effects</strong> – Many of the medications used to treat RA, including nonsteroidal antiinflammatory drugs (NSAIDs), glucocorticoids, and both conventional synthetic and biologic disease-modifying antirheumatic drugs (DMARDs), are associated with neurologic complications. (See <a class="local">'Drugs'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">DeQuattro K, Imboden JB. Neurologic Manifestations of Rheumatoid Arthritis. Rheum Dis Clin North Am 2017; 43:561.</a></li><li><a class="nounderline abstract_t">Puéchal X, Said G, Hilliquin P, et al. Peripheral neuropathy with necrotizing vasculitis in rheumatoid arthritis. A clinicopathologic and prognostic study of thirty-two patients. Arthritis Rheum 1995; 38:1618.</a></li><li><a class="nounderline abstract_t">Said G, Lacroix C. Primary and secondary vasculitic neuropathy. J Neurol 2005; 252:633.</a></li><li><a class="nounderline abstract_t">Ostrowski RA, Takagishi T, Robinson J. Rheumatoid arthritis, spondyloarthropathies, and relapsing polychondritis. Handb Clin Neurol 2014; 119:449.</a></li><li><a class="nounderline abstract_t">Rida MA, El Najjar M, Merashli M. Neurologic Manifestations of Rheumatoid Arthritis: A Case of Cerebral Vasculitis Treated With Rituximab. Arch Rheumatol 2019; 34:238.</a></li><li><a class="nounderline abstract_t">Agarwal V, Singh R, Wiclaf, et al. A clinical, electrophysiological, and pathological study of neuropathy in rheumatoid arthritis. Clin Rheumatol 2008; 27:841.</a></li><li><a class="nounderline abstract_t">Biswas M, Chatterjee A, Ghosh SK, et al. Prevalence, types, clinical associations, and determinants of peripheral neuropathy in rheumatoid patients. Ann Indian Acad Neurol 2011; 14:194.</a></li><li><a class="nounderline abstract_t">Bhattacharyya S, Helfgott SM. Neurologic complications of systemic lupus erythematosus, sjögren syndrome, and rheumatoid arthritis. Semin Neurol 2014; 34:425.</a></li><li><a class="nounderline abstract_t">Scott DG, Bacon PA, Tribe CR. Systemic rheumatoid vasculitis: a clinical and laboratory study of 50 cases. Medicine (Baltimore) 1981; 60:288.</a></li><li><a class="nounderline abstract_t">Makol A, Crowson CS, Wetter DA, et al. Vasculitis associated with rheumatoid arthritis: a case-control study. Rheumatology (Oxford) 2014; 53:890.</a></li><li><a class="nounderline abstract_t">Ward MM. Decreases in rates of hospitalizations for manifestations of severe rheumatoid arthritis, 1983-2001. Arthritis Rheum 2004; 50:1122.</a></li><li><a class="nounderline abstract_t">Nyhäll-Wåhlin BM, Petersson IF, Jacobsson C, et al. Extra-articular manifestations in a community-based sample of patients with rheumatoid arthritis: incidence and relationship to treatment with TNF inhibitors. Scand J Rheumatol 2012; 41:434.</a></li><li><a class="nounderline abstract_t">Watts RA, Mooney J, Lane SE, Scott DG. Rheumatoid vasculitis: becoming extinct? Rheumatology (Oxford) 2004; 43:920.</a></li><li><a class="nounderline abstract_t">Nadeau SE. Neurologic manifestations of connective tissue disease. Neurol Clin 2002; 20:151.</a></li><li><a class="nounderline abstract_t">Fugate JE, Claassen DO, Cloft HJ, et al. Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings. Mayo Clin Proc 2010; 85:427.</a></li><li><a class="nounderline abstract_t">Beck DO, Corbett JJ. Seizures due to central nervous system rheumatoid meningovasculitis. Neurology 1983; 33:1058.</a></li><li><a class="nounderline abstract_t">Kim RC, Collins GH. The neuropathology of rheumatoid disease. Hum Pathol 1981; 12:5.</a></li><li><a class="nounderline abstract_t">Mandybur TI. Cerebral amyloid angiopathy: possible relationship to rheumatoid vasculitis. Neurology 1979; 29:1336.</a></li><li><a class="nounderline abstract_t">Ramos M, Mandybur TI. Cerebral vasculitis in rheumatoid arthritis. Arch Neurol 1975; 32:271.</a></li><li><a class="nounderline abstract_t">Singleton JD, West SG, Reddy VV, Rak KM. Cerebral vasculitis complicating rheumatoid arthritis. South Med J 1995; 88:470.</a></li><li><a class="nounderline abstract_t">STEINER JW, GELBLOOM AJ. Intracranial manifestations in two cases of systemic rheumatoid disease. Arthritis Rheum 1959; 2:537.</a></li><li><a class="nounderline abstract_t">Watson P, Fekete J, Deck J. Central nervous system vasculitis in rheumatoid arthritis. Can J Neurol Sci 1977; 4:269.</a></li><li><a class="nounderline abstract_t">Caballol Pons N, Montalà N, Valverde J, et al. Isolated cerebral vasculitis associated with rheumatoid arthritis. Joint Bone Spine 2010; 77:361.</a></li><li><a class="nounderline abstract_t">Sigal LH. The neurologic presentation of vasculitic and rheumatologic syndromes. A review. Medicine (Baltimore) 1987; 66:157.</a></li><li><a class="nounderline abstract_t">Mrabet D, Meddeb N, Ajlani H, et al. Cerebral vasculitis in a patient with rheumatoid arthritis. Joint Bone Spine 2007; 74:201.</a></li><li><a class="nounderline abstract_t">Das S, Sinha D, Ghosal A, Purkayastha S. A case of central nervous system vasculitis secondary to rheumatoid arthritis treated successfully with mycophenolate. Mod Rheumatol Case Rep 2023; 7:130.</a></li><li><a class="nounderline abstract_t">Guadalupe Loya-de la Cerda D, Avilés-Solís JC, Delgado-Montemayor MJ, et al. Isolated rheumatoid arthritis-associated cerebral vasculitis: a diagnostic challenge. Joint Bone Spine 2013; 80:88.</a></li><li><a class="nounderline abstract_t">Xiao Y, Yang J, Xia J, et al. Spinal subarachnoid haemorrhage secondary to spinal rheumatoid vasculitis: a case report. BMC Neurol 2021; 21:465.</a></li><li><a class="nounderline abstract_t">Bathon JM, Moreland LW, DiBartolomeo AG. Inflammatory central nervous system involvement in rheumatoid arthritis. Semin Arthritis Rheum 1989; 18:258.</a></li><li><a class="nounderline abstract_t">Bekkelund SI, Pierre-Jerome C, Husby G, Mellgren SI. Quantitative cerebral MR in rheumatoid arthritis. AJNR Am J Neuroradiol 1995; 16:767.</a></li><li><a class="nounderline abstract_t">Takahashi M, Yamamoto J, Idei M, et al. Multiple intracranial nodules associated with rheumatoid arthritis: case report. Neurol Med Chir (Tokyo) 2014; 54:317.</a></li><li><a class="nounderline abstract_t">Friedman H. Intraspinal rheumatoid nodule causing nerve root compression. Case report. J Neurosurg 1970; 32:689.</a></li><li><a class="nounderline abstract_t">Jackson CG, Chess RL, Ward JR. A case of rheumatoid nodule formation within the central nervous system and review of the literature. J Rheumatol 1984; 11:237.</a></li><li><a class="nounderline abstract_t">Kim RC, Collins GH, Parisi JE. Rheumatoid nodule formation within the choroid plexus. Report of a second case. Arch Pathol Lab Med 1982; 106:83.</a></li><li><a class="nounderline abstract_t">Contin JU, Oka M. Unusual cardiac, pulmonary and meningeal involvement in rheumatoid arthritis. Report of a case. Dis Chest 1966; 49:552.</a></li><li><a class="nounderline abstract_t">Sunter JP. Rheumatoid disease with involvement of the leptomeninges presenting as symptomatic epilepsy. Beitr Pathol 1977; 161:194.</a></li><li><a class="nounderline abstract_t">Nesbitt C, Willshire L, Quan D, et al. Leptomeningeal rheumatoid nodules: diagnosis and failed therapeutics. J Clin Neurosci 2015; 22:425.</a></li><li><a class="nounderline abstract_t">Hauge T, Magnaes B, Løken AC, de Graaf AS. Treatment of rheumatoid pachymeningitis involving the entire thoracic region. Scand J Rheumatol 1978; 7:209.</a></li><li><a class="nounderline abstract_t">Patatanian E, Thompson DF. A review of methotrexate-induced accelerated nodulosis. Pharmacotherapy 2002; 22:1157.</a></li><li><a class="nounderline abstract_t">Ahmed SS, Arnett FC, Smith CA, et al. The HLA-DRB1*0401 allele and the development of methotrexate-induced accelerated rheumatoid nodulosis: a follow-up study of 79 Caucasian patients with rheumatoid arthritis. Medicine (Baltimore) 2001; 80:271.</a></li><li><a class="nounderline abstract_t">Sautner J, Rintelen B, Leeb BF. Rituximab as effective treatment in a case of severe subcutaneous nodulosis in rheumatoid arthritis. Rheumatology (Oxford) 2013; 52:1535.</a></li><li><a class="nounderline abstract_t">Chowdhry V, Kumar N, Lachance DH, et al. An unusual presentation of rheumatoid meningitis. J Neuroimaging 2005; 15:286.</a></li><li><a class="nounderline abstract_t">Starosta MA, Brandwein SR. Clinical manifestations and treatment of rheumatoid pachymeningitis. Neurology 2007; 68:1079.</a></li><li><a class="nounderline abstract_t">Bourgeois P, Rivest J, Bocti C. Rheumatoid meningitis presenting with stroke-like episodes. Neurology 2014; 82:1564.</a></li><li><a class="nounderline abstract_t">Magaki S, Chang E, Hammond RR, et al. Two cases of rheumatoid meningitis. Neuropathology 2016; 36:93.</a></li><li><a class="nounderline abstract_t">Brüggemann N, Gottschalk S, Holl-Ulrich K, et al. Cranial pachymeningitis: a rare neurological syndrome with heterogeneous aetiology. J Neurol Neurosurg Psychiatry 2010; 81:294.</a></li><li><a class="nounderline abstract_t">Schmid L, Müller M, Treumann T, et al. Induction of complete and sustained remission of rheumatoid pachymeningitis by rituximab. Arthritis Rheum 2009; 60:1632.</a></li><li><a class="nounderline abstract_t">Trabelsi M, Romand X, Gilson M, et al. Rheumatoid Meningitis a Rare Extra-Articular Manifestation of Rheumatoid Arthritis: Report of 6 Cases and Literature Review. J Clin Med 2020; 9.</a></li><li><a class="nounderline abstract_t">Parsons AM, Aslam F, Grill MF, et al. Rheumatoid Meningitis: Clinical Characteristics, Diagnostic Evaluation, and Treatment. Neurohospitalist 2020; 10:88.</a></li><li><a class="nounderline abstract_t">Zhang H, Wan Y, Mei Z, et al. Case Report: Rheumatoid meningitis with positive NMDAR antibody: A case treated with intravenous immunoglobulin. Front Immunol 2022; 13:971934.</a></li><li><a class="nounderline abstract_t">Nissen MS, Nilsson AC, Forsberg J, et al. Use of Cerebrospinal Fluid Biomarkers in Diagnosis and Monitoring of Rheumatoid Meningitis. Front Neurol 2019; 10:666.</a></li><li><a class="nounderline abstract_t">Roy B, Uphoff DF, Silverman IE. Rheumatoid Meningitis Presenting With Multiple Strokelike Episodes. JAMA Neurol 2015; 72:1073.</a></li><li><a class="nounderline abstract_t">Ikeda K, Takazawa T, Ito H, et al. Rheumatoid leptomeningitis: radiological alteration of cerebral hypoperfusion and subarachnoid lesions. Intern Med 2010; 49:1911.</a></li><li><a class="nounderline abstract_t">Tsuzaki K, Nakamura T, Okumura H, et al. Rheumatoid Meningitis Occurring during Etanercept Treatment. Case Rep Neurol Med 2017; 2017:7638539.</a></li><li><a class="nounderline abstract_t">Seago S, Stroberg E, Metting A. Rheumatoid meningitis associated with infliximab. Proc (Bayl Univ Med Cent) 2016; 29:204.</a></li><li><a class="nounderline abstract_t">Cavazzana I, Taraborelli M, Fredi M, et al. Aseptic meningitis occurring during anti-TNF-alpha therapy in rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol 2014; 32:732.</a></li><li><a class="nounderline abstract_t">Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases. Arthritis Rheum 2009; 60:3761.</a></li><li><a class="nounderline abstract_t">Clifford DB, Ances B, Costello C, et al. Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol 2011; 68:1156.</a></li><li><a class="nounderline abstract_t">Nakano KK. Neurologic complications of rheumatoid arthritis. Orthop Clin North Am 1975; 6:861.</a></li><li><a class="nounderline abstract_t">Ray M, Curtis JR, Baddley JW. A case report of progressive multifocal leucoencephalopathy (PML) associated with adalimumab. Ann Rheum Dis 2014; 73:1429.</a></li><li><a class="nounderline abstract_t">Anada M, Tohyama M, Oda Y, et al. Progressive Multifocal Leukoencephalopathy during Tocilizumab Treatment for Rheumatoid Arthritis. Intern Med 2020; 59:2053.</a></li><li><a class="nounderline abstract_t">González-Suárez I, Aguilar-Amat MJ, Trigueros M, et al. Leukoencephalopathy due to oral methotrexate. Cerebellum 2014; 13:178.</a></li><li><a class="nounderline abstract_t">Lach B, Connolly B, Wüthrich C, Koralnik IJ. Inflammatory infratentorial progressive multifocal leukoencephalopathy in a patient with rheumatoid arthritis. Neuropathology 2014; 34:39.</a></li><li><a class="nounderline abstract_t">Zakzook SI, Yunus MB, Mulconrey DS. Hyperviscosity syndrome in rheumatoid arthritis with Felty's syndrome: case report and review of the literature. Clin Rheumatol 2002; 21:82.</a></li><li><a class="nounderline abstract_t">Solomon DH, Kremer J, Curtis JR, et al. Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity. Ann Rheum Dis 2010; 69:1920.</a></li><li><a class="nounderline abstract_t">Solomon DH, Reed GW, Kremer JM, et al. Disease activity in rheumatoid arthritis and the risk of cardiovascular events. Arthritis Rheumatol 2015; 67:1449.</a></li><li><a class="nounderline abstract_t">Micha R, Imamura F, Wyler von Ballmoos M, et al. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol 2011; 108:1362.</a></li><li><a class="nounderline abstract_t">Barnabe C, Martin BJ, Ghali WA. Systematic review and meta-analysis: anti-tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res (Hoboken) 2011; 63:522.</a></li><li><a class="nounderline abstract_t">Aviña-Zubieta JA, Choi HK, Sadatsafavi M, et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008; 59:1690.</a></li><li><a class="nounderline abstract_t">Bacani AK, Gabriel SE, Crowson CS, et al. Noncardiac vascular disease in rheumatoid arthritis: increase in venous thromboembolic events? Arthritis Rheum 2012; 64:53.</a></li><li><a class="nounderline abstract_t">Nadareishvili Z, Michaud K, Hallenbeck JM, Wolfe F. Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: a nested, case-control study. Arthritis Rheum 2008; 59:1090.</a></li><li><a class="nounderline abstract_t">Solomon DH, Goodson NJ, Katz JN, et al. Patterns of cardiovascular risk in rheumatoid arthritis. Ann Rheum Dis 2006; 65:1608.</a></li><li><a class="nounderline abstract_t">Lindhardsen J, Ahlehoff O, Gislason GH, et al. Risk of atrial fibrillation and stroke in rheumatoid arthritis: Danish nationwide cohort study. BMJ 2012; 344:e1257.</a></li><li><a class="nounderline abstract_t">Liao TL, Lin CH, Chen HH, et al. Significant Associations of Neurological Complications of Herpes Zoster With Stroke in Rheumatoid Arthritis Patients. J Am Heart Assoc 2017; 6.</a></li><li><a class="nounderline abstract_t">Sivri A, Güler-Uysal F. The electroneurophysiological evaluation of rheumatoid arthritis patients. Clin Rheumatol 1998; 17:416.</a></li><li><a class="nounderline abstract_t">Sim MK, Kim DY, Yoon J, et al. Assessment of peripheral neuropathy in patients with rheumatoid arthritis who complain of neurologic symptoms. Ann Rehabil Med 2014; 38:249.</a></li><li><a class="nounderline abstract_t">Sakthiswary R, Singh R. Has the median nerve involvement in rheumatoid arthritis been overemphasized? Rev Bras Reumatol Engl Ed 2017; 57:122.</a></li><li><a class="nounderline abstract_t">Wiberg A, Smillie RW, Dupré S, et al. Replication of epidemiological associations of carpal tunnel syndrome in a UK population-based cohort of over 400,000 people. J Plast Reconstr Aesthet Surg 2022; 75:1034.</a></li><li><a class="nounderline abstract_t">Herbison GJ, Teng C, Martin JH, Ditunno JF Jr. Carpal tunnel syndrome in rheumatoid arthritis. Am J Phys Med 1973; 52:68.</a></li><li><a class="nounderline abstract_t">Muramatsu K, Tanaka H, Taguchi T. Peripheral neuropathies of the forearm and hand in rheumatoid arthritis: diagnosis and options for treatment. Rheumatol Int 2008; 28:951.</a></li><li><a class="nounderline abstract_t">Ogawa H, Akaike A, Ishimaru D, et al. Posterior interosseous nerve palsy related to rheumatoid synovitis of the elbow. Mod Rheumatol 2007; 17:327.</a></li><li><a class="nounderline abstract_t">White SH, Goodfellow JW, Mowat A. Posterior interosseous nerve palsy in rheumatoid arthritis. J Bone Joint Surg Br 1988; 70:468.</a></li><li><a class="nounderline abstract_t">Lee KH, Lee CH, Lee BG, et al. The incidence of carpal tunnel syndrome in patients with rheumatoid arthritis. Int J Rheum Dis 2015; 18:52.</a></li><li><a class="nounderline abstract_t">Baylan SP, Paik SW, Barnert AL, et al. Prevalence of the tarsal tunnel syndrome in rheumatoid arthritis. Rheumatol Rehabil 1981; 20:148.</a></li><li><a class="nounderline abstract_t">Grabois M, Puentes J, Lidsky M. Tarsal tunnel syndrome in rheumatoid arthritis. Arch Phys Med Rehabil 1981; 62:401.</a></li><li><a class="nounderline abstract_t">McGuigan L, Burke D, Fleming A. Tarsal tunnel syndrome and peripheral neuropathy in rheumatoid disease. Ann Rheum Dis 1983; 42:128.</a></li><li><a class="nounderline abstract_t">Tatsumura M, Mishima H, Shiina I, et al. Femoral nerve palsy caused by a huge iliopectineal synovitis extending to the iliac fossa in a rheumatoid arthritis case. Mod Rheumatol 2008; 18:81.</a></li><li><a class="nounderline abstract_t">Nakano KK. The entrapment neuropathies of rheumatoid arthritis. Orthop Clin North Am 1975; 6:837.</a></li><li><a class="nounderline abstract_t">Brick JE, Brick JF. Neurologic manifestations of rheumatologic disease. Neurol Clin 1989; 7:629.</a></li><li><a class="nounderline abstract_t">PALLIS CA, SCOTT JT. PERIPHERAL NEUROPATHY IN RHEUMATOID ARTHRITIS. Br Med J 1965; 1:1141.</a></li><li><a class="nounderline abstract_t">Chang DJ, Paget SA. Neurologic complications of rheumatoid arthritis. Rheum Dis Clin North Am 1993; 19:955.</a></li><li><a class="nounderline abstract_t">Hurd ER. Extraarticular manifestations of rheumatoid arthritis. Semin Arthritis Rheum 1979; 8:151.</a></li><li><a class="nounderline abstract_t">FERGUSON RH, SLOCUMB CH. Peripheral neuropathy in rheumatoid arthritis. Bull Rheum Dis 1961; 11:251.</a></li><li><a class="nounderline abstract_t">Bekkelund SI, Torbergsen T, Husby G, Mellgren SI. Myopathy and neuropathy in rheumatoid arthritis. A quantitative controlled electromyographic study. J Rheumatol 1999; 26:2348.</a></li><li><a class="nounderline abstract_t">Fleming A, Dodman S, Crown JM, Corbett M. Extra-articular features in early rheumatoid disease. Br Med J 1976; 1:1241.</a></li><li><a class="nounderline abstract_t">Chamberlain MA, Bruckner FE. Rheumatoid neuropathy. Clinical and electrophysiological features. Ann Rheum Dis 1970; 29:609.</a></li><li><a class="nounderline abstract_t">Haslock DI, Wright V, Harriman DG. Neuromuscular disorders in rheumatoid arthritis. A motor-point muscle biopsy study. Q J Med 1970; 39:335.</a></li><li><a class="nounderline abstract_t">Weller RO, Bruckner FE, Chamberlain MA. Rheumatoid neuropathy: a histological and electrophysiological study. J Neurol Neurosurg Psychiatry 1970; 33:592.</a></li><li><a class="nounderline abstract_t">Conn DL, McDuffie FC, Dyck PJ. Immunopathologic study of sural nerves in rheumatoid arthritis. Arthritis Rheum 1972; 15:135.</a></li><li><a class="nounderline abstract_t">Fleischmann RM. Progressive multifocal leukoencephalopathy following rituximab treatment in a patient with rheumatoid arthritis. Arthritis Rheum 2009; 60:3225.</a></li><li><a class="nounderline abstract_t">Goldman JA, Casey HL, McIlwain H, et al. Limited plasmapheresis in rheumatoid arthritis with vasculitis. Arthritis Rheum 1979; 22:1146.</a></li><li><a class="nounderline abstract_t">Edmonds ME, Jones TC, Saunders WA, Sturrock RD. Autonomic neuropathy in rheumatoid arthritis. Br Med J 1979; 2:173.</a></li><li><a class="nounderline abstract_t">Geenen R, Godaert GL, Jacobs JW, et al. Diminished autonomic nervous system responsiveness in rheumatoid arthritis of recent onset. J Rheumatol 1996; 23:258.</a></li><li><a class="nounderline abstract_t">Aggarwal D, Singla S. Prevalence of Autonomic Neuropathy in Patients of Rheumatoid Arthritis and Its Correlation with Disease Severity. J Clin Diagn Res 2017; 11:OC09.</a></li><li><a class="nounderline abstract_t">Syngle V, Syngle A, Garg N, et al. Predictors of autonomic neuropathy in rheumatoid arthritis. Auton Neurosci 2016; 201:54.</a></li><li><a class="nounderline abstract_t">Reza MJ, Verity MA. Neuromuscular manifestations of rheumatoid arthritis: A clinical and histomorphological analysis. Clin Rheum Dis 1977; 3:565.</a></li><li><a class="nounderline abstract_t">Targowski T. Sarcopaenia and rheumatoid arthritis. Reumatologia 2017; 55:84.</a></li><li><a class="nounderline abstract_t">Halla JT, Koopman WJ, Fallahi S, et al. Rheumatoid myositis. Clinical and histologic features and possible pathogenesis. Arthritis Rheum 1984; 27:737.</a></li><li><a class="nounderline abstract_t">Haslock DI, Harriman DF, Wright V. Neuromuscular disorders associated with rheumatoid arthritis. Ann Rheum Dis 1970; 29:197.</a></li><li><a class="nounderline abstract_t">Hanaoka BY, Ithurburn MP, Rigsbee CA, et al. Chronic Inflammation in Rheumatoid Arthritis and Mediators of Skeletal Muscle Pathology and Physical Impairment: A Review. Arthritis Care Res (Hoboken) 2019; 71:173.</a></li><li><a class="nounderline abstract_t">Askari A, Vignos PJ Jr, Moskowitz RW. Steroid myopathy in connective tissue disease. Am J Med 1976; 61:485.</a></li><li><a class="nounderline abstract_t">Aguila LA, Lopes MR, Pretti FZ, et al. Clinical and laboratory features of overlap syndromes of idiopathic inflammatory myopathies associated with systemic lupus erythematosus, systemic sclerosis, or rheumatoid arthritis. Clin Rheumatol 2014; 33:1093.</a></li><li><a class="nounderline abstract_t">Meyer A, Lefevre G, Bierry G, et al. In antisynthetase syndrome, ACPA are associated with severe and erosive arthritis: an overlapping rheumatoid arthritis and antisynthetase syndrome. Medicine (Baltimore) 2015; 94:e523.</a></li><li><a class="nounderline abstract_t">Wegelius O, Pasternack A, Kuhlbäck B. Muscular involvement in rheumatoid arthritis. Acta Rheumatol Scand 1969; 15:257.</a></li><li><a class="nounderline abstract_t">Fam AG, Gordon DA, Sarkozi J, et al. Neurologic complications associated with gold therapy for rheumatoid arthritis. J Rheumatol 1984; 11:700.</a></li></ol></div><div id="topicVersionRevision">Topic 7480 Version 29.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29061242" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Neurologic Manifestations of Rheumatoid Arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7488283" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Peripheral neuropathy with necrotizing vasculitis in rheumatoid arthritis. A clinicopathologic and prognostic study of thirty-two patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15806339" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Primary and secondary vasculitic neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24365312" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Rheumatoid arthritis, spondyloarthropathies, and relapsing polychondritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31497773" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Neurologic Manifestations of Rheumatoid Arthritis: A Case of Cerebral Vasculitis Treated With Rituximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18084807" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : A clinical, electrophysiological, and pathological study of neuropathy in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22028533" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Prevalence, types, clinical associations, and determinants of peripheral neuropathy in rheumatoid patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25369438" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Neurologic complications of systemic lupus erythematosus, sjögren syndrome, and rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7242322" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Systemic rheumatoid vasculitis: a clinical and laboratory study of 50 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24441152" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Vasculitis associated with rheumatoid arthritis: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15077294" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Decreases in rates of hospitalizations for manifestations of severe rheumatoid arthritis, 1983-2001.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22813208" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Extra-articular manifestations in a community-based sample of patients with rheumatoid arthritis: incidence and relationship to treatment with TNF inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15126674" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Rheumatoid vasculitis: becoming extinct?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11754305" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Neurologic manifestations of connective tissue disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20435835" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6683802" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Seizures due to central nervous system rheumatoid meningovasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6259049" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The neuropathology of rheumatoid disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/573377" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Cerebral amyloid angiopathy: possible relationship to rheumatoid vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/235911" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Cerebral vasculitis in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7716604" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Cerebral vasculitis complicating rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13834207" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Intracranial manifestations in two cases of systemic rheumatoid disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/597801" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Central nervous system vasculitis in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20471884" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Isolated cerebral vasculitis associated with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3553845" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The neurologic presentation of vasculitic and rheumatologic syndromes. A review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17336121" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Cerebral vasculitis in a patient with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35537857" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : A case of central nervous system vasculitis secondary to rheumatoid arthritis treated successfully with mycophenolate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22858148" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Isolated rheumatoid arthritis-associated cerebral vasculitis: a diagnostic challenge.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34847873" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Spinal subarachnoid haemorrhage secondary to spinal rheumatoid vasculitis: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2658068" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Inflammatory central nervous system involvement in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7611036" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Quantitative cerebral MR in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24140764" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Multiple intracranial nodules associated with rheumatoid arthritis: case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5442595" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Intraspinal rheumatoid nodule causing nerve root compression. Case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6726721" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : A case of rheumatoid nodule formation within the central nervous system and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6895833" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Rheumatoid nodule formation within the choroid plexus. Report of a second case.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5935898" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Unusual cardiac, pulmonary and meningeal involvement in rheumatoid arthritis. Report of a case.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/597105" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Rheumatoid disease with involvement of the leptomeninges presenting as symptomatic epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25533052" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Leptomeningeal rheumatoid nodules: diagnosis and failed therapeutics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/734378" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Treatment of rheumatoid pachymeningitis involving the entire thoracic region.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12222551" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : A review of methotrexate-induced accelerated nodulosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11470988" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The HLA-DRB1*0401 allele and the development of methotrexate-induced accelerated rheumatoid nodulosis: a follow-up study of 79 Caucasian patients with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23329684" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Rituximab as effective treatment in a case of severe subcutaneous nodulosis in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15951415" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : An unusual presentation of rheumatoid meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17389318" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Clinical manifestations and treatment of rheumatoid pachymeningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24647026" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Rheumatoid meningitis presenting with stroke-like episodes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26350538" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Two cases of rheumatoid meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20185466" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Cranial pachymeningitis: a rare neurological syndrome with heterogeneous aetiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19479865" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Induction of complete and sustained remission of rheumatoid pachymeningitis by rituximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32471260" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Rheumatoid Meningitis a Rare Extra-Articular Manifestation of Rheumatoid Arthritis: Report of 6 Cases and Literature Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32373270" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Rheumatoid Meningitis: Clinical Characteristics, Diagnostic Evaluation, and Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36275742" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Case Report: Rheumatoid meningitis with positive NMDAR antibody: A case treated with intravenous immunoglobulin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31293505" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Use of Cerebrospinal Fluid Biomarkers in Diagnosis and Monitoring of Rheumatoid Meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26368353" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Rheumatoid Meningitis Presenting With Multiple Strokelike Episodes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20823656" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Rheumatoid leptomeningitis: radiological alteration of cerebral hypoperfusion and subarachnoid lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28286682" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Rheumatoid Meningitis Occurring during Etanercept Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27034572" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Rheumatoid meningitis associated with infliximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25198168" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Aseptic meningitis occurring during anti-TNF-alpha therapy in rheumatoid arthritis and ankylosing spondylitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19950261" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21555606" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1099511" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Neurologic complications of rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24618264" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : A case report of progressive multifocal leucoencephalopathy (PML) associated with adalimumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32448834" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Progressive Multifocal Leukoencephalopathy during Tocilizumab Treatment for Rheumatoid Arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24068485" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Leukoencephalopathy due to oral methotrexate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23683127" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Inflammatory infratentorial progressive multifocal leukoencephalopathy in a patient with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11954894" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Hyperviscosity syndrome in rheumatoid arthritis with Felty's syndrome: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20444756" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25776112" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Disease activity in rheumatoid arthritis and the risk of cardiovascular events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21855836" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20957658" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Systematic review and meta-analysis: anti-tumor necrosis factorαtherapy and cardiovascular events in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19035419" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21905005" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Noncardiac vascular disease in rheumatoid arthritis: increase in venous thromboembolic events?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18668583" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: a nested, case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16793844" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Patterns of cardiovascular risk in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22403267" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Risk of atrial fibrillation and stroke in rheumatoid arthritis: Danish nationwide cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28724649" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Significant Associations of Neurological Complications of Herpes Zoster With Stroke in Rheumatoid Arthritis Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9805193" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : The electroneurophysiological evaluation of rheumatoid arthritis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24855620" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Assessment of peripheral neuropathy in patients with rheumatoid arthritis who complain of neurologic symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28343616" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Has the median nerve involvement in rheumatoid arthritis been overemphasized?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34916160" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Replication of epidemiological associations of carpal tunnel syndrome in a UK population-based cohort of over 400,000 people.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4349387" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Carpal tunnel syndrome in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18528693" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Peripheral neuropathies of the forearm and hand in rheumatoid arthritis: diagnosis and options for treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17694268" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Posterior interosseous nerve palsy related to rheumatoid synovitis of the elbow.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3372573" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Posterior interosseous nerve palsy in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25196946" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : The incidence of carpal tunnel syndrome in patients with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7280489" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Prevalence of the tarsal tunnel syndrome in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7259475" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Tarsal tunnel syndrome in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6303230" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Tarsal tunnel syndrome and peripheral neuropathy in rheumatoid disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18180875" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Femoral nerve palsy caused by a huge iliopectineal synovitis extending to the iliac fossa in a rheumatoid arthritis case.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1099510" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : The entrapment neuropathies of rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2671638" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Neurologic manifestations of rheumatologic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14273515" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : PERIPHERAL NEUROPATHY IN RHEUMATOID ARTHRITIS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8265831" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Neurologic complications of rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/370982" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Extraarticular manifestations of rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13698897" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Peripheral neuropathy in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10555889" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Myopathy and neuropathy in rheumatoid arthritis. A quantitative controlled electromyographic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1083759" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Extra-articular features in early rheumatoid disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4322141" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Rheumatoid neuropathy. Clinical and electrophysiological features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4394609" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Neuromuscular disorders in rheumatoid arthritis. A motor-point muscle biopsy study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4320255" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Rheumatoid neuropathy: a histological and electrophysiological study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4337482" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Immunopathologic study of sural nerves in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19877057" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Progressive multifocal leukoencephalopathy following rituximab treatment in a patient with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/39566" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Limited plasmapheresis in rheumatoid arthritis with vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/466338" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Autonomic neuropathy in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8882029" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Diminished autonomic nervous system responsiveness in rheumatoid arthritis of recent onset.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28571182" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Prevalence of Autonomic Neuropathy in Patients of Rheumatoid Arthritis and Its Correlation with Disease Severity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27503343" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Predictors of autonomic neuropathy in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Neuromuscular manifestations of rheumatoid arthritis: A clinical and histomorphological analysis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28539680" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Sarcopaenia and rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6378209" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Rheumatoid myositis. Clinical and histologic features and possible pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5427428" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Neuromuscular disorders associated with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30295435" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Chronic Inflammation in Rheumatoid Arthritis and Mediators of Skeletal Muscle Pathology and Physical Impairment: A Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/973643" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Steroid myopathy in connective tissue disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24989017" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Clinical and laboratory features of overlap syndromes of idiopathic inflammatory myopathies associated with systemic lupus erythematosus, systemic sclerosis, or rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25997035" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : In antisynthetase syndrome, ACPA are associated with severe and erosive arthritis: an overlapping rheumatoid arthritis and antisynthetase syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5379133" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Muscular involvement in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6096543" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Neurologic complications associated with gold therapy for rheumatoid arthritis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
